SCAI Statement on Thyroid Monitoring in Young Children Receiving Iodinated Contrast Media
SCAI believes that the current data is insufficient to warrant the course of action described within the recent Food and Drug Administration Drug Safety Communication and that further studies are needed to define at-risk groups accurately, clarify the risks of ICM exposure, and provide rational monitoring and treatment guidelines.